Katalin Kariko

Katalin Kariko was born on January 17, 1955, in Szolnok, a town on the Tisza River in central Hungary, and grew up in Kisujszallas, a small community on the Great Hungarian Plain. Her father worked as a butcher and her mother as a bookkeeper. The family lived in a modest adobe house that lacked running water, a refrigerator, and a television for much of her childhood ^[1]. She has often traced her fascination with biology to watching her father at work and to the plants and animals that surrounded her in the countryside.

Her talent showed early. As a schoolgirl she placed third in a national biology competition in Hungary, and teachers encouraged her toward science at a time when few women from rural backgrounds pursued research careers ^[2]. She went on to study biology at the University of Szeged, one of Hungary's leading research universities, where she became interested in nucleic acids, the molecules that carry genetic information.

Kariko earned her doctorate in biochemistry at Szeged in 1982 and began her research career at the Biological Research Centre of the Hungarian Academy of Sciences in the same city. There she worked on RNA and on lipid-based methods for delivering genetic material into cells, themes that would define the rest of her working life ^[3]. When the laboratory lost its funding in 1985, she faced a choice that would reshape her future: stay in Hungary without a research position, or leave.

In 1985 Kariko, her husband Bela Francia, and their two-year-old daughter Susan left Hungary for the United States. Because of restrictions on taking currency out of the country, the family famously hid the proceeds from selling their car, about 900 pounds sterling exchanged on the black market, inside their daughter's teddy bear ^[1]. Kariko had accepted a postdoctoral position at Temple University in Philadelphia, where she worked on RNA in clinical trials involving patients with blood disorders.

After Temple she moved briefly to the Uniformed Services University of the Health Sciences in Maryland before joining the University of Pennsylvania in 1989 as a research assistant professor ^[3]. At Penn she pursued an idea that most of her colleagues considered impractical: that messenger RNA, the short-lived molecule cells use to translate genes into proteins, could be manufactured in the laboratory and given to patients as a therapy. In principle, mRNA could instruct a patient's own cells to produce any protein a doctor wanted, from clotting factors to vaccine antigens.

The idea attracted little money. Grant applications were rejected repeatedly, and in 1995 the University of Pennsylvania demoted her from the tenure track after she failed to secure major funding ^[2]. The demotion came in the same period she was diagnosed with cancer and her husband was stranded in Hungary by a visa problem. She later described this as the low point of her career, yet she chose to stay at the bench and keep working on mRNA rather than abandon the field. These Katalin Kariko facts, the demotion, the rejections, the persistence, have become central to how her story is told, and any honest Katalin Kariko biography has to reckon with how close the field came to losing her.

A chance meeting at a photocopier changed the direction of mRNA science. In 1997 Kariko struck up a conversation with Drew Weissman, an immunologist who had recently arrived at Penn and wanted to develop a vaccine against HIV ^[4]. Weissman had funding and an interest in vaccines; Kariko had deep expertise in making RNA. They agreed to collaborate, with Kariko supplying synthetic mRNA for Weissman's experiments on dendritic cells, the sentinels of the immune system.

The collaboration quickly ran into a wall. Whenever they introduced lab-made mRNA into cells or animals, it triggered a strong inflammatory reaction. The immune system treated the synthetic molecule as an invader, destroying it before it could produce much protein and causing side effects that would make any therapy unusable. Solving that problem became the pair's obsession for years.

Their answer came in 2005. Kariko and Weissman showed that replacing one of mRNA's four building blocks, the nucleoside uridine, with naturally occurring modified versions such as pseudouridine made the molecule nearly invisible to the immune sensors that had been sounding the alarm ^[4]. Modified mRNA not only avoided inflammation, it also produced far more protein. The finding, published in the journal Immunity, initially drew modest attention, but it removed the central obstacle to using mRNA as a medicine ^[5]. The two scientists patented the technology, and it was later licensed to companies that would build on it, including BioNTech in Germany and Moderna in the United States.

Penn never gave Kariko a permanent faculty home for her mRNA work, and in 2013 she left the university to join BioNTech, then a small German biotechnology company in Mainz co-founded by Ugur Sahin and Ozlem Tureci. She became a senior vice president, overseeing the company's mRNA programs, while keeping an adjunct appointment at Penn ^[3]. At the time BioNTech had no approved products and was known mainly for experimental cancer immunotherapies; she has recalled that some colleagues joked the company did not even have a website.

When the SARS-CoV-2 virus emerged in late 2019, the modified-mRNA platform Kariko and Weissman had created was ready. BioNTech partnered with Pfizer to develop a COVID-19 vaccine encoding the virus's spike protein, and Moderna developed its own vaccine on the same nucleoside-modified principle. Both vaccines proved roughly 95 percent effective in large clinical trials and received emergency authorization in December 2020, less than a year after the viral genome was published ^[6].

Billions of doses of mRNA vaccines were administered worldwide during the pandemic, and public health researchers have credited COVID-19 vaccination with saving millions of lives in the first year of the rollout alone ^[6]. For anyone asking who was Katalin Kariko before 2020, the answer was a little-known specialist; within months she became one of the most celebrated scientists in the world. She stepped down from her executive role at BioNTech in 2022, remaining an adviser, and took up a professorship at her alma mater, the University of Szeged, along with an adjunct professorship at the University of Pennsylvania.

On October 2, 2023, the Nobel Assembly at the Karolinska Institute announced that Kariko and Weissman had won the Nobel Prize in Physiology or Medicine for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19 ^[7]. Kariko became the thirteenth woman to receive the medicine prize and one of the few Hungarian women ever awarded a Nobel in the sciences. She learned of the award from a phone call at home, having been asleep when the committee first tried to reach her.

The Nobel capped an extraordinary run of recognition. Among many Katalin Kariko achievements honored between 2021 and 2023 were the Lasker-DeBakey Clinical Medical Research Award, the Breakthrough Prize in Life Sciences, the Japan Prize, the Tang Prize, the L'Oreal-UNESCO For Women in Science Award, and Time magazine's designation of the vaccine scientists as 2021 Heroes of the Year ^[2]. Universities across Europe and North America awarded her honorary degrees.

In 2023 she published a memoir, Breaking Through: My Life in Science, which recounts her path from rural Hungary through decades of rejection to the pandemic vaccines ^[8]. The book was widely reviewed and reinforced her public role as an advocate for persistence in research and for scientists working outside prestigious career tracks.

Kariko has been married to Bela Francia, an engineer, since her years in Szeged. The couple settled in the Philadelphia suburbs after emigrating and raised their daughter there. That daughter, Susan Francia, became a world-class athlete: she rowed for the United States and won Olympic gold medals in the women's eight at the Beijing Games in 2008 and the London Games in 2012 ^[1]. Kariko has joked that for years she was best known as the mother of an Olympic champion.

Colleagues and journalists who have profiled her describe an unusually single-minded scientist. For decades she worked long hours at the bench, often seven days a week, and she has said she never earned more than 60,000 dollars a year before leaving academia for BioNTech ^[2]. She has spoken frequently about handling rejection by focusing on what she could control, an attitude she credits partly to the stress-management writings of fellow Hungarian scientist Hans Selye. She holds dual Hungarian and American nationality and divides her time between the United States and Hungary.

Kariko's scientific legacy rests on a simple but transformative insight: that chemistry, not just biology, determines how the immune system reads a molecule. Nucleoside modification turned mRNA from a laboratory curiosity into a programmable medicine, and the platform is now being tested against influenza, HIV, malaria, cystic fibrosis, and a range of cancers ^[5]. Researchers regard the 2005 Kariko-Weissman paper as one of the foundational publications of twenty-first century biomedicine.

Her career has also become a case study in how scientific institutions evaluate ideas and people. The fact that a future Nobel laureate was demoted, denied grants for decades, and never granted tenure at the university where she made her key discovery is now cited in debates about research funding, career structures, and the treatment of immigrant and female scientists ^[7]. Kariko herself has used her platform to argue that unfashionable basic research deserves patient support.

Beyond the laboratory, she has become a national figure in Hungary and a role model far beyond it, particularly for young women in science. Schools, scholarships, and awards now carry her name, and her memoir is read as much for its lessons about resilience as for its science ^[8]. Whatever mRNA medicine achieves in the decades ahead, the vaccines that helped end the acute phase of a global pandemic already secure her place among the most influential biochemists of her era.